APO Research
Talk to an analyst

APO RESEARCH · REPORT

COX-2 Selective NSAIDs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global COX-2 Selective NSAIDs Market Outlook and Growth Opportunities 2026

29 December 2025190 pages

Choose your research edition.

Industry ResearchCOX-2 Selective NSAIDs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal COX-2 Selective NSAIDs Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal COX-2 Selective NSAIDs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal COX-2 Selective NSAIDs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal COX-2 Selective NSAIDs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global COX-2 Selective NSAIDs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for COX-2 Selective NSAIDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for COX-2 Selective NSAIDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for COX-2 Selective NSAIDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the COX-2 Selective NSAIDs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the COX-2 Selective NSAIDs market include Teva, Merck, Mylan, Jiangsu Hengrui Medicine, Pfizer, Lupin and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global COX-2 Selective NSAIDs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of COX-2 Selective NSAIDs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents COX-2 Selective NSAIDs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the COX-2 Selective NSAIDs market size, projected growth trends, production technologies, key applications, and end-use industries.

COX-2 Selective NSAIDs Segment by Company

Teva

Merck

Mylan

Jiangsu Hengrui Medicine

Pfizer

Lupin

Apotex

COX-2 Selective NSAIDs Segment by Type

Valdecoxib

Rofecoxib

Celecoxib

Etoricoxib

COX-2 Selective NSAIDs Segment by Application

Hospital

Clinic

Other

COX-2 Selective NSAIDs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global COX-2 Selective NSAIDs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions COX-2 Selective NSAIDs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify COX-2 Selective NSAIDs significant trends, drivers, influence factors in global and regions.

6. To analyze COX-2 Selective NSAIDs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COX-2 Selective NSAIDs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of COX-2 Selective NSAIDs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COX-2 Selective NSAIDs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the COX-2 Selective NSAIDs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global COX-2 Selective NSAIDs industry.

Chapter 3: Detailed analysis of COX-2 Selective NSAIDs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of COX-2 Selective NSAIDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of COX-2 Selective NSAIDs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. COX-2 Selective NSAIDs Industry Trends Table 2. COX-2 Selective NSAIDs Industry Drivers Table 3. COX-2 Selective NSAIDs Industry Opportunities and Challenges Table 4. COX-2 Selective NSAIDs Industry Restraints Table 5. Global COX-2 Selective NSAIDs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global COX-2 Selective NSAIDs Revenue Share by Company (2021-2026) Table 7. Global COX-2 Selective NSAIDs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global COX-2 Selective NSAIDs Sales Volume Share by Company (2021-2026) Table 9. Global COX-2 Selective NSAIDs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global COX-2 Selective NSAIDs Company Ranking, (2024-2026) & (USD Million) Table 11. Global COX-2 Selective NSAIDs Key Company Manufacturing Base & Headquarters Table 12. Global COX-2 Selective NSAIDs Company, Product Type & Application Table 13. Global COX-2 Selective NSAIDs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global COX-2 Selective NSAIDs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Valdecoxib Table 18. Significant Companies of Rofecoxib Table 19. Significant Companies of Celecoxib Table 20. Significant Companies of Etoricoxib Table 21. Global COX-2 Selective NSAIDs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global COX-2 Selective NSAIDs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global COX-2 Selective NSAIDs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global COX-2 Selective NSAIDs Sales Volume Share by Type (2021-2026) Table 25. Global COX-2 Selective NSAIDs Sales Volume Share by Type (2027-2032) Table 26. Global COX-2 Selective NSAIDs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global COX-2 Selective NSAIDs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global COX-2 Selective NSAIDs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global COX-2 Selective NSAIDs Sales Value Share by Type (2021-2026) Table 30. Global COX-2 Selective NSAIDs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Other Table 34. Global COX-2 Selective NSAIDs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global COX-2 Selective NSAIDs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global COX-2 Selective NSAIDs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global COX-2 Selective NSAIDs Sales Volume Share by Application (2021-2026) Table 38. Global COX-2 Selective NSAIDs Sales Volume Share by Application (2027-2032) Table 39. Global COX-2 Selective NSAIDs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global COX-2 Selective NSAIDs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global COX-2 Selective NSAIDs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global COX-2 Selective NSAIDs Sales Value Share by Application (2021-2026) Table 43. Global COX-2 Selective NSAIDs Sales Value Share by Application (2027-2032) Table 44. Global COX-2 Selective NSAIDs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global COX-2 Selective NSAIDs Sales by Region (2021-2026) & (K Units) Table 46. Global COX-2 Selective NSAIDs Sales Market Share by Region (2021-2026) Table 47. Global COX-2 Selective NSAIDs Sales by Region (2027-2032) & (K Units) Table 48. Global COX-2 Selective NSAIDs Sales Market Share by Region (2027-2032) Table 49. Global COX-2 Selective NSAIDs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global COX-2 Selective NSAIDs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global COX-2 Selective NSAIDs Sales Value Share by Region (2021-2026) Table 52. Global COX-2 Selective NSAIDs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global COX-2 Selective NSAIDs Sales Value Share by Region (2027-2032) Table 54. Global COX-2 Selective NSAIDs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global COX-2 Selective NSAIDs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global COX-2 Selective NSAIDs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global COX-2 Selective NSAIDs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global COX-2 Selective NSAIDs Sales by Country (2021-2026) & (K Units) Table 59. Global COX-2 Selective NSAIDs Sales Market Share by Country (2021-2026) Table 60. Global COX-2 Selective NSAIDs Sales by Country (2027-2032) & (K Units) Table 61. Global COX-2 Selective NSAIDs Sales Market Share by Country (2027-2032) Table 62. Global COX-2 Selective NSAIDs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global COX-2 Selective NSAIDs Sales Value Market Share by Country (2021-2026) Table 64. Global COX-2 Selective NSAIDs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global COX-2 Selective NSAIDs Sales Value Market Share by Country (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Teva COX-2 Selective NSAIDs Product Portfolio Table 70. Teva Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Merck COX-2 Selective NSAIDs Product Portfolio Table 75. Merck Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Mylan COX-2 Selective NSAIDs Product Portfolio Table 80. Mylan Recent Development Table 81. Jiangsu Hengrui Medicine Company Information Table 82. Jiangsu Hengrui Medicine Business Overview Table 83. Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product Portfolio Table 85. Jiangsu Hengrui Medicine Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Pfizer COX-2 Selective NSAIDs Product Portfolio Table 90. Pfizer Recent Development Table 91. Lupin Company Information Table 92. Lupin Business Overview Table 93. Lupin COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lupin COX-2 Selective NSAIDs Product Portfolio Table 95. Lupin Recent Development Table 96. Apotex Company Information Table 97. Apotex Business Overview Table 98. Apotex COX-2 Selective NSAIDs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Apotex COX-2 Selective NSAIDs Product Portfolio Table 100. Apotex Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. COX-2 Selective NSAIDs Distributors List Table 104. COX-2 Selective NSAIDs Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. COX-2 Selective NSAIDs Product Image Figure 2. Global COX-2 Selective NSAIDs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 4. Global COX-2 Selective NSAIDs Sales (2021-2032) & (K Units) Figure 5. Global COX-2 Selective NSAIDs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global COX-2 Selective NSAIDs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Valdecoxib Image Figure 10. Rofecoxib Image Figure 11. Celecoxib Image Figure 12. Etoricoxib Image Figure 13. Global COX-2 Selective NSAIDs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global COX-2 Selective NSAIDs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global COX-2 Selective NSAIDs Sales Volume Share by Type (2021-2032) Figure 16. Global COX-2 Selective NSAIDs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global COX-2 Selective NSAIDs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global COX-2 Selective NSAIDs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global COX-2 Selective NSAIDs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global COX-2 Selective NSAIDs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global COX-2 Selective NSAIDs Sales Volume Share by Application (2021-2032) Figure 25. Global COX-2 Selective NSAIDs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global COX-2 Selective NSAIDs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global COX-2 Selective NSAIDs Sales Value Share by Application (2021-2032) Figure 28. Global COX-2 Selective NSAIDs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global COX-2 Selective NSAIDs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global COX-2 Selective NSAIDs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global COX-2 Selective NSAIDs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 33. North America COX-2 Selective NSAIDs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe COX-2 Selective NSAIDs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific COX-2 Selective NSAIDs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 39. South America COX-2 Selective NSAIDs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa COX-2 Selective NSAIDs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa COX-2 Selective NSAIDs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. COX-2 Selective NSAIDs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. COX-2 Selective NSAIDs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Valdecoxib
  • Rofecoxib
  • Celecoxib
  • Etoricoxib
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Teva
  • Merck
  • Mylan
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Lupin
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global COX-2 Selective NSAIDs Sales Value (2021-2032)
  4. 1.2.2 Global COX-2 Selective NSAIDs Sales Volume (2021-2032)
  5. 1.2.3 Global COX-2 Selective NSAIDs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 COX-2 Selective NSAIDs Market Dynamics
  1. 2.1 COX-2 Selective NSAIDs Industry Trends
  2. 2.2 COX-2 Selective NSAIDs Industry Drivers
  3. 2.3 COX-2 Selective NSAIDs Industry Opportunities and Challenges
  4. 2.4 COX-2 Selective NSAIDs Industry Restraints
3 COX-2 Selective NSAIDs Market by Company
  1. 3.1 Global COX-2 Selective NSAIDs Company Revenue Ranking in 2025
  2. 3.2 Global COX-2 Selective NSAIDs Revenue by Company (2021-2026)
  3. 3.3 Global COX-2 Selective NSAIDs Sales Volume by Company (2021-2026)
  4. 3.4 Global COX-2 Selective NSAIDs Average Price by Company (2021-2026)
  5. 3.5 Global COX-2 Selective NSAIDs Company Ranking (2024-2026)
  6. 3.6 Global COX-2 Selective NSAIDs Company Manufacturing Base and Headquarters
  7. 3.7 Global COX-2 Selective NSAIDs Company Product Type and Application
  8. 3.8 Global COX-2 Selective NSAIDs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global COX-2 Selective NSAIDs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 COX-2 Selective NSAIDs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 COX-2 Selective NSAIDs Market by Type
  1. 4.1 COX-2 Selective NSAIDs Type Introduction
  2. 4.1.1 Valdecoxib
  3. 4.1.2 Rofecoxib
  4. 4.1.3 Celecoxib
  5. 4.1.4 Etoricoxib
  6. 4.2 Global COX-2 Selective NSAIDs Sales Volume by Type
  7. 4.2.1 Global COX-2 Selective NSAIDs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global COX-2 Selective NSAIDs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global COX-2 Selective NSAIDs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global COX-2 Selective NSAIDs Sales Value by Type
  11. 4.3.1 Global COX-2 Selective NSAIDs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global COX-2 Selective NSAIDs Sales Value by Type (2021-2032)
  13. 4.3.3 Global COX-2 Selective NSAIDs Sales Value Share by Type (2021-2032)
5 COX-2 Selective NSAIDs Market by Application
  1. 5.1 COX-2 Selective NSAIDs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global COX-2 Selective NSAIDs Sales Volume by Application
  6. 5.2.1 Global COX-2 Selective NSAIDs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global COX-2 Selective NSAIDs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global COX-2 Selective NSAIDs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global COX-2 Selective NSAIDs Sales Value by Application
  10. 5.3.1 Global COX-2 Selective NSAIDs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global COX-2 Selective NSAIDs Sales Value by Application (2021-2032)
  12. 5.3.3 Global COX-2 Selective NSAIDs Sales Value Share by Application (2021-2032)
6 COX-2 Selective NSAIDs Regional Sales and Value Analysis
  1. 6.1 Global COX-2 Selective NSAIDs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global COX-2 Selective NSAIDs Sales by Region (2021-2032)
  3. 6.2.1 Global COX-2 Selective NSAIDs Sales by Region: 2021-2026
  4. 6.2.2 Global COX-2 Selective NSAIDs Sales by Region (2027-2032)
  5. 6.3 Global COX-2 Selective NSAIDs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global COX-2 Selective NSAIDs Sales Value by Region (2021-2032)
  7. 6.4.1 Global COX-2 Selective NSAIDs Sales Value by Region: 2021-2026
  8. 6.4.2 Global COX-2 Selective NSAIDs Sales Value by Region (2027-2032)
  9. 6.5 Global COX-2 Selective NSAIDs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America COX-2 Selective NSAIDs Sales Value (2021-2032)
  12. 6.6.2 North America COX-2 Selective NSAIDs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe COX-2 Selective NSAIDs Sales Value (2021-2032)
  15. 6.7.2 Europe COX-2 Selective NSAIDs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific COX-2 Selective NSAIDs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific COX-2 Selective NSAIDs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America COX-2 Selective NSAIDs Sales Value (2021-2032)
  21. 6.9.2 South America COX-2 Selective NSAIDs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa COX-2 Selective NSAIDs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa COX-2 Selective NSAIDs Sales Value Share by Country, 2025 VS 2032
7 COX-2 Selective NSAIDs Country-level Sales and Value Analysis
  1. 7.1 Global COX-2 Selective NSAIDs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global COX-2 Selective NSAIDs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global COX-2 Selective NSAIDs Sales by Country (2021-2032)
  4. 7.3.1 Global COX-2 Selective NSAIDs Sales by Country (2021-2026)
  5. 7.3.2 Global COX-2 Selective NSAIDs Sales by Country (2027-2032)
  6. 7.4 Global COX-2 Selective NSAIDs Sales Value by Country (2021-2032)
  7. 7.4.1 Global COX-2 Selective NSAIDs Sales Value by Country (2021-2026)
  8. 7.4.2 Global COX-2 Selective NSAIDs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt COX-2 Selective NSAIDs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt COX-2 Selective NSAIDs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt COX-2 Selective NSAIDs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva COX-2 Selective NSAIDs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck COX-2 Selective NSAIDs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan COX-2 Selective NSAIDs Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Jiangsu Hengrui Medicine
  20. 8.4.1 Jiangsu Hengrui Medicine Company Information
  21. 8.4.2 Jiangsu Hengrui Medicine Business Overview
  22. 8.4.3 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product Portfolio
  24. 8.4.5 Jiangsu Hengrui Medicine Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer COX-2 Selective NSAIDs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Lupin
  32. 8.6.1 Lupin Company Information
  33. 8.6.2 Lupin Business Overview
  34. 8.6.3 Lupin COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lupin COX-2 Selective NSAIDs Product Portfolio
  36. 8.6.5 Lupin Recent Developments
  37. 8.7 Apotex
  38. 8.7.1 Apotex Company Information
  39. 8.7.2 Apotex Business Overview
  40. 8.7.3 Apotex COX-2 Selective NSAIDs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Apotex COX-2 Selective NSAIDs Product Portfolio
  42. 8.7.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 COX-2 Selective NSAIDs Value Chain Analysis
  2. 9.1.1 COX-2 Selective NSAIDs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 COX-2 Selective NSAIDs Sales Mode & Process
  6. 9.2 COX-2 Selective NSAIDs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 COX-2 Selective NSAIDs Distributors
  9. 9.2.3 COX-2 Selective NSAIDs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst